Recombinant Cynomolgus/Rhesus SLAM/CD150 His-tag Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Signaling lymphocytic activation molecule (SLAM), also known as SLAMF1 and CD150, is the founding member of the SLAM subfamily of the CD2 protein family (1, 2). SLAM is a single-pass type I membrane glycoprotein that functions as an adhesion molecule and plays an active role in the regulation of innate and adaptive immunity (1, 2, 4). Mature SLAM consists of an extracellular domain (ECD) containing an Ig-like V-type domain and an Ig-like C2-type domain, a helical transmembrane domain, and a cytoplasmic tail containing 2 immunoreceptor tyrosine-based switch motifs (ITSM) (3, 4). The ECD of cynomolgus SLAM shares 97% amino acid identity with human SLAM. In human, several isoforms resulting from alternative splicing have been identified with functional diversity (4). SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells, and it is up-regulated on activated B cells and CD4+ and CD8+ T cells (4-6). SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 phenotype in CD8+ T cells that is characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity (7, 8). SLAM also plays a role in activation of the PI3K-Akt signaling pathway through its association with the adapter molecule SAP (9). In humans, SLAM functions as a cellular entry receptor for measles virus (10, 11). SLAM deregulation is associated with genomic complexity and independently predicts a worse outcome in chronic lymphocytic leukemia (CLL) (12).

Array 10971-SL

• SLAM/CD150 Antibodies
• SLAM/CD150 Antibody Pair
• SLAM/CD150 Proteins
• SLAM/CD150 ELISA
• SLAM/CD150 Proteins and Enzymes